EyePoint (EYPT) Asset Writedowns and Impairment (2011 - 2023)

EyePoint (EYPT) reported Asset Writedowns and Impairment of $533000.0 for Q2 2023, down 97.43% sequentially from $20.7 million in Q4 2022.

EyePoint (EYPT) Asset Writedowns and Impairment (2011 - 2023) Analysis & Trends

EyePoint (EYPT) has 3 years of Asset Writedowns and Impairment data on file, last reported at $533000.0 in Q2 2023.

For the quarter ending Q2 2023, Asset Writedowns and Impairment changed N/A year-over-year to $533000.0; the trailing twelve-month figure through Sep 2024 stood at $533000.0 (down 97.49% YoY), and the FY2023 full-year result was $693000.0, down 96.65% from the prior year.
Asset Writedowns and Impairment retreated to $533000.0 in Q2 2023, from $20.7 million in the prior quarter.
In the past five years, Asset Writedowns and Impairment ranged from a high of $20.7 million in Q4 2022 to a low of $533000.0 in Q2 2023.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	66,621.14 Bn	66,620.85 Bn	-
2	Nanobiotix	1,915.18 Bn	1,915.11 Bn	-
3	Akari Therapeutics	1,014.18 Bn	1,014.18 Bn	-
4	BeOne Medicines	471.27 Bn	466.48 Bn	1.35 Bn
5	Vertex Pharmaceuticals	121.81 Bn	114.57 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	69.58 Bn	60.82 Bn	3.31 Bn
7	Belite Bio	62.72 Bn	62.72 Bn	-
8	Argenx Se	55.51 Bn	50.33 Bn	1.41 Bn
9	Revolution Medicines	37.35 Bn	37.35 Bn	-
10	EyePoint	1.07 Mn	-221.48 Mn	168,000.00

Download Data